Liora Sklair-Tavron

Title: Liora Sklair-Tavron: Innovating Treatment for Cocaine Abuse

Introduction: Liora Sklair-Tavron is a prominent inventor based in Zichron Yaakov, Israel. She is recognized for her contributions to the field of pharmaceuticals, specifically in developing innovative methods for treating substance abuse. Liora holds a significant patent that showcases her expertise and dedication to improving healthcare solutions.

Latest Patents: Liora Sklair-Tavron has been awarded one patent titled "BChE albumin fusions for the treatment of cocaine abuse." This patent details a method aimed at attenuating the biological effects of cocaine exposure in primates. The method involves administering a BChE-albumin fusion protein with specific amino acid substitutions, namely A227S, S315G, A356W, and Y360G. The patent highlights that the effective amount of this fusion protein can significantly reduce the adverse effects associated with cocaine exposure.

Career Highlights: Liora is currently associated with Teva Pharmaceutical Industries Limited, a leading global pharmaceutical company. Her work at Teva emphasizes her commitment to advancing pharmaceutical innovation and developing effective treatment options for addiction and other critical health issues.

Collaborations: Throughout her career, Liora has collaborated with notable colleagues such as Moti Rosenstock and Liron Shemesh-Darvish. These collaborative efforts have fostered a creative and innovative workspace, enhancing the development of cutting-edge therapeutic solutions.

Conclusion: Liora Sklair-Tavron represents the spirit of innovation in the pharmaceutical industry. Her patent for the treatment of cocaine abuse stands as a testament to her expertise and commitment to improving patient outcomes. As she continues her work at Teva Pharmaceutical Industries Limited, Liora's contributions will undoubtedly play a crucial role in shaping the future of addiction treatment.